While lung cancer has been the leading cause of cancer-related deaths for many years in
the United States, incidence and mortality statistics–among other measures–vary widely …

Lung cancer has a poor prognosis; over half of people diagnosed with lung cancer die
within one year of diagnosis and the 5-year survival is less than 18%. Non-small cell lung …

PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor,
demonstrated superior progression-free survival (PFS) and improved health-related quality …

Background Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and
ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity …

Background Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has
robust efficacy in patients with ALK-positive non–small-cell lung cancer (NSCLC) that is …

Introduction In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line
(ALTA-1L), which is a study of brigatinib in ALK inhibitor–naive advanced ALK-positive …

Importance Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase
(ALK), has shown systemic and central nervous system efficacy for patients withALK-positive …

Haplotyping of human chromosomes is a prerequisite for cataloguing the full repertoire of
genetic variation. We present a microfluidics-based, linked-read sequencing technology that …

The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …

Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …